Capstan Medical Secures $110 Million in Oversubscribed Series C Financing to Advance Robotic Structural Heart Platform

Capstan Medical Announces Successful Completion of $110 Million Oversubscribed Series C Financing to Support Market Launch of Its Robotic Structural Heart Solutions. This round was led by Eclipse, with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.

Capstan Medical Inc. stated that its minimally invasive solutions aim to overcome the limitations of current treatment options by combining novel cardiac valve implants with advanced catheter technology, fully realized through a robotic platform, to treat a broader range of patients.

"Transcatheter interventions have the potential to significantly expand treatment options for millions of patients with valvular heart disease. At Capstan, we believe our robotic platform, with its comprehensive portfolio of implants, is uniquely positioned to address the critical needs of this underserved patient population," said Maggie Nixon, CEO of Capstan Medical. "We have assembled the right team at the right time to achieve this goal, with strong support from our investors."

Eclipse partner Justin Butler said:"We are at a turning point where robotics will play a significant role in providing life-saving solutions for millions of patients worldwide,Capstan Medical is at the forefront of this wave with its robotic solutions for structural heart disease.”